Related Experiment Videos
Recombinant factor VIIa. An update on its clinical use
Massimo Franchini1, Marco Zaffanello, Dino Veneri
1Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Ospedale Policlinico, Piazzale Ludovico Scuro, 37134 Verona, Italy. massimo.franchini@mail.azosp.vr.it
Thrombosis and Haemostasis
|June 22, 2005
Summary
Recombinant activated factor VII (rFVIIa) effectively treats bleeding in hemophilia patients with inhibitors. This review explores its established and emerging uses for various bleeding disorders.
Area of Science:
- Hematology
- Pharmacology
- Clinical Medicine
Background:
- Recombinant activated factor VII (rFVIIa) is a hemostatic agent.
- It is established for treating bleeding in hemophilia patients with inhibitors to factors VIII or IX.
- Its use has expanded to other hemostatic abnormalities.
Purpose of the Study:
- To review the current knowledge on rFVIIa therapy.
- To cover both well-standardized and newer clinical applications.
- To examine the literature on rFVIIa's efficacy and safety.
Main Methods:
- Literature search was performed.
- Review of existing studies and clinical data.
- Analysis of standardized and emerging uses of rFVIIa.
Main Results:
- rFVIIa is effective for bleeding in hemophilia with inhibitors.
- rFVIIa is increasingly used for other congenital and acquired bleeding disorders.
- The review covers established indications and less characterized applications.
Conclusions:
- rFVIIa is a valuable therapeutic option for specific bleeding conditions.
- Further research may clarify its role in less common hemostatic abnormalities.
- The review provides a comprehensive overview of rFVIIa's clinical utility.